- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | Vaso Corporation Announces Financial Results for Second Quarter of 2026 | 385 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive... ► Artikel lesen | |
| 03.08. | Vaso Corporation Completes Sale of NetWolves Network Services to COEO Solutions | 275 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 31.07. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Vaso Corporation beruft Shaun McMeans in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 23.07. | Vaso appoints Shaun McMeans to board of directors | 1 | Investing.com | ||
| 23.07. | Vaso Corporation Appoints Shaun McMeans to Board of Directors | 196 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., July 23, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 23.07. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | VASO Global Raises Over £5M in Venture, Grant, and Debt Funding Round | 1 | FinSMEs | ||
| 30.06. | VASO Global wins support for recycled glass panels | 1 | The Construction Index | ||
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2026 | 421 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 08.05. | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | VASO Corp - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | Vasomedical reports Q4 results, revenue flat at $27M | 1 | Seeking Alpha | ||
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025 | 228 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 452 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 591 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11.25 | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 379 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRAZENECA | 144,85 | +0,14 % | Astrazeneca-Brustkrebsmedikament verfehlt Ziel in Spätphasenstudie | DJ Astrazeneca-Brustkrebsmedikament verfehlt Ziel in Spätphasenstudie
Von Adria Calatayud
DOW JONES--Astrazeneca hat einen Rückschlag bei einer Brustkrebs-Pille in einer klinischen Spätphasenstudie... ► Artikel lesen | |
| EYEPOINT | 3,460 | +2,98 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| IONIS PHARMACEUTICALS | 39,220 | +1,37 % | Guggenheim cuts Ionis Pharmaceuticals stock price target on sales outlook | ||
| CSPC PHARMA | 1,006 | +1,99 % | CSPC PHARMA (01093): NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM | ||
| SELLAS LIFE SCIENCES | 10,000 | 0,00 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 463,10 | +0,09 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ACADIA PHARMACEUTICALS | 23,430 | -1,39 % | Acadia Pharmaceuticals Inc.: European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 4,420 | -1,78 % | Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? | ||
| CHUGAI PHARMACEUTICAL | 37,990 | +1,06 % | Roche-Tochter Chugai baut Einsatz seines Krebstests in Japan aus | ||
| SAVARA | 4,616 | -1,37 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 3,100 | 0,00 % | Galectin Therapeutics: Belapectin vor entscheidender Phase-III-Studie bei MASH-Zirrhose | ||
| BIODEXA PHARMACEUTICALS | 0,730 | 0,00 % | Biodexa Pharmaceuticals enters warrant exercise transaction for $2.3M gross proceeds; shares rise | ||
| NEURIZON THERAPEUTICS | 0,040 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Change of Director's Interest Notice |
Das Unternehmen VASO CORPORATION kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VASO CORPORATION finden Sie auf Wallstreet Online.